Synaps Dx is dedicated to transforming the diagnosis of Alzheimer’s disease (AD). Operating a CLIA-certified laboratory, we offer DISCERN™, the first commercially available test to accurately detect AD (>95%). Granted Breakthrough Status by the FDA, DISCERN™ provides a convenient, accurate, minimally invasive diagnosis of Alzheimer’s disease. Through analysis of one (1) small in-office skin biopsy provided by a referring physician, SDx offers a reliable and accurate alternative to traditional diagnostic methods. Our diagnostic biomarkers have been confirmed by neuropathological validation (NIH “Gold Standard”).